Parkman Healthcare Partners LLC Sells 142,233 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE)

Parkman Healthcare Partners LLC decreased its stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) by 41.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 202,973 shares of the company’s stock after selling 142,233 shares during the period. Parkman Healthcare Partners LLC owned 1.38% of VYNE Therapeutics worth $382,000 as of its most recent filing with the SEC.

Separately, Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Trading Down 1.7 %

Shares of VYNE Therapeutics stock opened at $2.83 on Wednesday. The company has a market cap of $41.74 million, a price-to-earnings ratio of -3.29 and a beta of 1.37. VYNE Therapeutics Inc. has a 1 year low of $1.57 and a 1 year high of $3.62. The company’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $2.20.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a research report on Friday, November 8th.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.